avatar

Auto-generated profile, based on publicly available information


Research Focus & Metrics

Representative Publications

View All Publications
16 April 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MSMasahiro Shuda
Masahiro Shuda
CVCelestino Velásquez
Celestino Velásquez
ECErdong Cheng
Erdong Cheng
DCDaniel G. Cordek
Daniel G. Cordek
HKHyun Jin Kwun
Hyun Jin Kwun
Patrick S. MoorePatrick S. Moore
Patrick S. Moore
Mitosis is commonly thought to be associated with reduced cap-dependent protein translation. Here we show an alternative control mechanism for maintaining cap-dependent translation during mitosis revealed by a viral oncoprotein, Merkel cell polyomavirus small T (MCV sT). We find MCV sT to be a promiscuous E3 ligase inhibitor targeting the anaphase-promoting complex, which increases cell mitogenesis. MCV sT binds through its Large T stabilization domain region to cell division cycle protein 20 (Cdc20) and, possibly, cdc20 homolog 1 (Cdh1) E3 ligase adapters. This activates cyclin-dependent kinase 1/cyclin B1 (CDK1/CYCB1) to directly hyperphosphorylate eukaryotic initiation factor 4E (eIF4E)-binding protein (4E-BP1) at authentic sites, generating a mitosis-specific, mechanistic target of rapamycin (mTOR) inhibitor-resistant δ phospho-isoform not present in G1-arrested cells. Recombinant 4E-BP1 inhibits capped mRNA reticulocyte translation, which is partially reversed by CDK1/CYCB1 phosphorylation of 4E-BP1. eIF4G binding to the eIF4E–m7GTP cap complex is resistant to mTOR inhibition during mitosis but sensitive during interphase. Flow cytometry, with and without sT, reveals an orthogonal pH3S10+ mitotic cell population having higher inactive p4E-BP1T37/T46+ saturation levels than pH3S10– interphase cells. Using a Click-iT flow cytometric assay to directly measure mitotic protein synthesis, we find that most new protein synthesis during mitosis is cap-dependent, a result confirmed using the eIF4E/4G inhibitor drug 4E1RCat. For most cell lines tested, cap-dependent translation levels were generally similar between mitotic and interphase cells, and the majority of new mitotic protein synthesis was cap-dependent. These findings suggest that mitotic cap-dependent translation is generally sustained during mitosis by CDK1 phosphorylation of 4E-BP1 even under conditions of reduced mTOR signaling. Significance Cancer cell proliferation is highly dependent on cap-dependent protein synthesis, which is generally assumed to be inhibited during mitosis. Using a viral oncoprotein that enforces mitosis, we show that CDK1 substitutes for mTOR interphase functions to phosphorylate eukaryotic initiation factor 4E-binding protein (4E-BP1) to a mitosis-specific δ isoform. Flow cytometric assays reveal that mitotic cells have high levels of inactivated 4E-BP1 and do not generally show specific loss of cap-dependent translation compared with interphase cells. This appears to be due to cyclin-dependent kinase 1 (CDK1) activity during mitosis. Mitotic cells typically represent less than 1% of all cells in bulk culture, and mitosis-arresting drugs, such as nocodazole, can directly inhibit mitotic protein translation, potentially explaining differences between our findings and previous studies showing reduced cap-dependent translation during mitosis.

11 July 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CVCelestino Velásquez
Celestino Velásquez
ECErdong Cheng
Erdong Cheng
MSMasahiro Shuda
Masahiro Shuda
PLPaula J. Lee-Oesterreich
Paula J. Lee-Oesterreich
LSLisa Pogge von Strandmann
Lisa Pogge von Strandmann
YCYuan Chang
Yuan Chang
Significance: Eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) hyperphosphorylation is implicated in various cancers. Mammalian target of rapamycin (mTOR) targeting of canonical sites—Thr37, Thr46, Ser65, and Thr70—inhibits 4E-BP1 translation repression activity and promotes protein synthesis, which in turn leads to overexpression of several cellular oncoproteins. In addition to the canonical sites, cyclin-dependent kinase 1 (CDK1) phosphorylates 4E-BP1 at Ser83 during mitosis, which interestingly does not affect translation. Rather, this phosphorylation site is permissive for Merkel cell polyomavirus small T viral oncoprotein-induced cell transformation. These findings shed light on a previously unidentified role for mitotic 4E-BP1 in cancer cell growth.

11 April 2018 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
CVCelestino Velásquez
Celestino Velásquez
YAYutaka Amako
Yutaka Amako
AHAlexis Harold
Alexis Harold
TTTuna Toptan
Tuna Toptan
YCYuan Chang
Yuan Chang
MSMasahiro Shuda
Masahiro Shuda
Merkel cell polyomavirus (MCV) plays a causal role in ∼80% of Merkel cell carcinomas (MCC). MCV is clonally integrated into the MCC tumor genome, which results in persistent expression of large T (LT) and small T (sT) antigen oncoproteins encoded by the early locus. In MCV-positive MCC tumors, LT is truncated by premature stop codons or deletions that lead to loss of the C-terminal origin binding (OBD) and helicase domains important for replication. The N-terminal Rb binding domain remains intact. MCV-positive cell lines derived from MCC explants have been valuable tools to study the molecular mechanism of MCV-induced Merkel cell carcinogenesis. Although all cell lines have integrated MCV and express truncated LT antigens, the molecular sizes of the LT proteins differ between cell lines. The copy number of integrated viral genome also varies across cell lines, leading to significantly different levels of viral protein expression. Nevertheless, these cell lines share phenotypic similarities in cell morphology, growth characteristics, and neuroendocrine marker expression. Several low-passage MCV-positive MCC cell lines have been established since the identification of MCV. We describe a new MCV-positive MCV cell line, CVG-1, with features distinct from previously reported cell lines. CVG-1 tumor cells grow in more discohesive clusters in loose round cell suspension, and individual cells show dramatic size heterogeneity. It is the first cell line to encode an MCV sT polymorphism resulting in a unique leucine (L) to proline (P) substitution mutation at amino acid 144. CVG-1 possesses a LT truncation pattern near identical to that of MKL-1 cells differing by the last two C-terminal amino acids and also shows an LT protein expression level similar to MKL-1. Viral T antigen knockdown reveals that, like other MCV-positive MCC cell lines, CVG-1 requires T antigen expression for cell proliferation.